WEHI-P8
WEHI-P8 is an orally active inhibitor targeting the papain-like protease (PLpro) of coronaviruses. WEHI-P8 againsts SARS-CoV-2 PLpro with an IC50 value of 12 nM. WEHI-P8 has good cellular activity with a EC50 of 298 nM. WEHI-P8 protects mice from SARS-CoV-2 induced long-term symptoms in lung and brain. WEHI-P8 can be used for post-acute sequelae of COVID-19 study[1].
Product Specifications
UNSPSC
12352005
Target
SARS-CoV
Related Pathways
Anti-infection
Applications
COVID-19-anti-virus
Field of Research
Infection
Smiles
CCO/N=C([C@@H]1CCCN(C1)[C@H]2CC[C@H](CC2)O)/C3=CC4=C(C=C(C=C4)OC)C=C3
Molecular Formula
C25H34N2O3
Molecular Weight
410.55
References & Citations
[1]M Bader S, et al. A novel PLpro inhibitor improves outcomes in a pre-clinical model of long COVID. Nat Commun. 2025 Apr 3;16 (1) :2900.
Shipping Conditions
Room temperature
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
Recombinant Arabidopsis thaliana Probable nicotianamine synthase 4 (NAS4)
Recombinant Arabidopsis thaliana Probable nicotianamine synthase 4 (NAS4)
Recombinant Arabidopsis thaliana Probable nicotianamine synthase 4 (NAS4)
Recombinant Arabidopsis thaliana Probable nicotianamine synthase 4 (NAS4)
